Cardiac Repair with a Novel Population of Mesenchymal Stem Cells Resident in the Human Heart

Stem Cells

Volumn 33, Issue 10, 2015, Pages 3100-3113

  Zhang, Yuan ^a   Sivakumaran, Priyadharshini ^a   Newcomb, Andrew E ^a,b,c   Hernandez, Damián ^a   Harris, Nicole ^a   Khanabdali, Ramin ^a,b   Liu, Guei Sheung ^a,d   Kelly, Darren J ^a   Pébay, Alice ^a,d   Hewitt, Alex W ^a,d   Boyle, Andrew ^e   Harvey, Richard ^f   Morrison, Wayne A ^a   Elliott, David A ^a,c,g   Dusting, Gregory J ^a   Lim, Shiang Y ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^d ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Adult stem cells; Heart; Mesenchymal stem cell; Myocardial infarction; W8B2

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CD163 ANTIGEN; HAND2 PROTEIN; ISL1 PROTEIN; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL ANTIGEN 1; STEM CELL FACTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; UNCLASSIFIED DRUG; W8B2 ANTIGEN; WT1 PROTEIN; CONDITIONED MEDIUM; CYTOKINE; MEMBRANE ANTIGEN; W8B2 PROTEIN, HUMAN;

ADULT; ADULT STEM CELL; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC RESIDENT STEM CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL STRUCTURE; CELL SURVIVAL; CHEMOTAXIS; CLONOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART ATRIUM APPENDAGE; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; SCAR; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE CELL; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECTS; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PHARMACOLOGY; TRANSPLANTATION;

ADULT; ADULT STEM CELLS; ANIMALS; ANTIGENS, SURFACE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RATS;

EID: 84942373431     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2101     Document Type: Article

References (37)

1. Bergmann O, Bhardwaj RD, Bernard S, et al., Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
2. Leri A, Kajstura J, Anversa P,. Role of cardiac stem cells in cardiac pathophysiology: A paradigm shift in human myocardial biology. Circ Res 2011; 109: 941-961.
3. Bearzi C, Rota M, Hosoda T, et al., Human cardiac stem cells. PNAS 2007; 104: 14068-14073.
4. Smith RR, Barile L, Cho HC, et al., Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007; 115: 896-908.
5. Bolli R, Chugh AR, D'Amario D, et al., Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011; 378: 1847-1857.
6. Makkar RR, Smith RR, Cheng K, et al., Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012; 379: 895-904.
7. Chong JJ, Chandrakanthan V, Xaymardan M, et al., Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell 2011; 9: 527-540.
8. Oskouei BN, Lamirault G, Joseph C, et al., Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med 2012; 1: 116-124.
9. Forte G, Pietronave S, Nardone G, et al., Human cardiac progenitor cell grafts as unrestricted source of supernumerary cardiac cells in healthy murine hearts. Stem Cells 2011; 29: 2051-2061.
10. Buhring HJ, Battula VL, Treml S, et al., Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007; 1106: 262-271.
11. Sobiesiak M, Sivasubramaniyan K, Hermann C, et al., The mesenchymal stem cell antigen MSCA-1 is identical to tissue non-specific alkaline phosphatase. Stem Cells Dev 2010; 19: 669-677.
12. Battula VL, Bareiss PM, Treml S, et al., Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation 2007; 75: 279-291.
13. Battula VL, Treml S, Bareiss PM, et al., Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009; 94: 173-184.
14. Lim SY, Sivakumaran P, Crombie DE, et al., Trichostatin A enhances differentiation of human induced pluripotent stem cells to cardiogenic cells for cardiac tissue engineering. Stem Cells Transl Med 2013; 2: 715-725.
15. Lim SY, Hsiao ST, Lokmic Z, et al., Ischemic preconditioning promotes intrinsic vascularization and enhances survival of implanted cells in an in vivo tissue engineering model. Tissue Eng Part A 2012; 18: 2210-2219.
16. Zhang Y, Elsik M, Edgley AJ, et al., A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. Int J Cardiol 2013; 168: 1174-1185.
17. Hsiao ST, Asgari A, Lokmic Z, et al., Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev 2012; 21: 2189-2203.
18. Tilkorn DJ, Bedogni A, Keramidaris E, et al., Implanted myoblast survival is dependent on the degree of vascularization in a novel delayed implantation/prevascularization tissue engineering model. Tissue Eng Part A 2010; 16: 165-178.
19. Bukoreshtliev NV, Wang X, Hodneland E, et al., Selective block of tunneling nanotube (TNT) formation inhibits intercellular organelle transfer between PC12 cells. FEBS Lett 2009; 583: 1481-1488.
20. Lou E, Fujisawa S, Morozov A, et al., Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS One 2012; 7: e33093.
21. Piao Y, Hung SS, Lim SY, et al., Efficient generation of integration-free human induced pluripotent stem cells from keratinocytes by simple transfection of episomal vectors. Stem Cells Transl Med 2014; 3: 787-791.
22. Martin-Puig S, Wang Z, Chien KR,. Lives of a heart cell: Tracing the origins of cardiac progenitors. Cell Stem Cell 2008; 2: 320-331.
23. Chong JJ, Reinecke H, Iwata M, et al., Progenitor cells identified by PDGFR-alpha expression in the developing and diseased human heart. Stem Cells Dev 2013; 22: 1932-1943.
24. Pfister O, Oikonomopoulos A, Sereti KI, et al., Role of the ATP-binding cassette transporter Abcg2 in the phenotype and function of cardiac side population cells. Circ Res 2008; 103: 825-835.
25. Rossini A, Frati C, Lagrasta C, et al., Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. Cardiovasc Res 2011; 89: 650-660.
26. Dominici M, Le Blanc K, Mueller I, et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
27. de Aguiar AM, Kuligovski C, da Costa MTBA, et al., Alkaline phosphatase-positive cells isolated from human hearts have mesenchymal stem cell characteristics. Stem Cell Discov 2011; 1: 71-80.
28. Furtado MB, Costa MW, Pranoto EA, et al., Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res 2014; 114: 1422-1434.
29. Yang X, Pabon L, Murry CE,. Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res 2014; 114: 511-523.
30. Chong JJ, Yang X, Don CW, et al., Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014; 510: 273-277.
31. Atoui R, Chiu RC,. Concise review: Immunomodulatory properties of mesenchymal stem cells in cellular transplantation: Update, controversies, and unknowns. Stem Cells Transl Med 2012; 1: 200-205.
32. de Almeida PE, Ransohoff JD, Nahid A, et al., Immunogenicity of pluripotent stem cells and their derivatives. Circ Res 2013; 112: 549-561.
33. Karabekian Z, Posnack NG, Sarvazyan N,. Immunological barriers to stem-cell based cardiac repair. Stem Cell Rev 2011; 7: 315-325.
34. Zheng SX, Weng YL, Zhou CQ, et al., Comparison of cardiac stem cells and mesenchymal stem cells transplantation on the cardiac electrophysiology in rats with myocardial infarction. Stem Cell Rev 2013; 9: 339-349.
35. Nahrendorf M, Swirski FK, Aikawa E, et al., The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
36. Aurora AB, Porrello ER, Tan W, et al., Macrophages are required for neonatal heart regeneration. J Clin Invest 2014; 124: 1382-1392.
37. Ben-Mordechai T, Holbova R, Landa-Rouben N, et al., Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol 2013; 62: 1890-1901.